

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/500,354	06/30/2004	Masayo Higashiyama	2004_1016A	2612
513 7590 04/30/2014 WENDEROTH, LIND & PONACK, L.L.P. 1030 15th Street, N.W.,			EXAMINER	
			FRAZIER, BARBARA S	
Suite 400 East Washington, DC 20005-1503			ART UNIT	PAPER NUMBER
			1611	
			NOTIFICATION DATE	DELIVERY MODE
			04/30/2014	ELECTRONIC

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

ddalecki@wenderoth.com eoa@wenderoth.com



	10/500,354	HIGASHIYAN	HIGASHIYAMA, MASAYO		
Office Action Summary	Examiner BARBARA FRAZIER	Art Unit 1611	AIA (First Inventor to File) Status No		
The MAILING DATE of this communication app	ears on the cover sheet with	h the correspondence	ce address		
Period for Reply					
A SHORTENED STATUTORY PERIOD FOR REPLY THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period w - Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	6(a). In no event, however, may a re ill apply and will expire SIX (6) MONT cause the application to become ABA	ply be timely filed HS from the mailing date of NDONED (35 U.S.C. § 133	this communication.		
Status					
1) Responsive to communication(s) filed on <u>28 Fe</u> A declaration(s)/affidavit(s) under 37 CFR 1.1 : 2a) This action is FINAL . 2b) This 3) An election was made by the applicant in responsible to the restriction requirement and election 4) Since this application is in condition for allowance.	30(b) was/were filed on action is non-final. onse to a restriction require have been incorporated in ce except for formal matte	ement set forth during to this action. ers, prosecution as t			
closed in accordance with the practice under E	x parte Quayle, 1935 C.D.	11, 453 O.G. 213.			
Disposition of Claims*					
5) Claim(s) 1.3,5-9 and 12-15 is/are pending in the 5a) Of the above claim(s) is/are withdraw 6) Claim(s) 14 is/are allowed. 7) Claim(s) 1.3,5-9,12,13 and 15 is/are rejected. 8) Claim(s) is/are objected to. 9) Claim(s) are subject to restriction and/or * If any claims have been determined allowable, you may be eliparticipating intellectual property office for the corresponding aphttp://www.uspto.gov/patents/init_events/pph/index.jsp or send Application Papers 10) The specification is objected to by the Examiner 11) The drawing(s) filed on is/are: a) access Applicant may not request that any objection to the corrections.	election requirement. gible to benefit from the Pate eplication. For more information an inquiry to <u>PPHfeedback@</u> epted or b) objected to be drawing(s) be held in abeyand	on, please see uspto.gov. by the Examiner. ce. See 37 CFR 1.85((a).		
Priority under 35 U.S.C. § 119 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). Certified copies: a) All b) Some** c) None of the: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). ** See the attached detailed Office action for a list of the certified copies not received.					
Attachment(s)					
1) Notice of References Cited (PTO-892) 2) Information Disclosure Statement(s) (PTO/SB/08a and/or PTO/S	3) 🔀 Interview Su	ummary (PTO-413) /Mail Date. <u>4/24/14</u> .			

Application No.

Applicant(s)



Application/Control Number: 10/500,354 Page 2

Art Unit: 1611

DETAILED ACTION

1. The present application is being examined under the pre-AIA first to invent provisions.

Examiner's Remarks

2. The Examiner notes that the proper status of claim 14 was inadvertently omitted from the previous Office action mailed 23 April 2014. The Office action mailed 23 April 2014 is hereby vacated; a corrected Office action follows.

Status of Claims

3. Claims 1, 3, 5-9, and 12-15 are pending in this application, and are examined.

Claim Rejections - 35 USC § 103

- 4. The following is a quotation of pre-AIA 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:
 - (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.
- 5. Claims 1, 3, 5-9, 12, 13, and 15 are rejected under 35 U.S.C. 103(a) as being unpatentable over Lehmussaari et al. ("Lehmussaari", US Patent 5,795,913, previously cited) in view of Kita et al. ("Kita", US Patent 6,307,052, previously cited) and optionally further in view of Araki et al. ("Araki", WO 01/80858).



Application/Control Number: 10/500,354 Page 3

Art Unit: 1611

2003/0139436 is the national stage entry of WO 01/80858, and thus serves as an English translation of WO 01/80858; accordingly, relevant passages will be taken from the US '436 reference.

Regarding claims 1 and 13, Lehmussaari teaches an ophthalmic composition in the form of a topical aqueous solution consisting essentially of an ophthalmologically active agent containing basic groups, an ion sensitive hydrophilic polymer containing acidic groups, and at least one salt selected from the group of inorganic salts and buffers in a total amount of from 0.01 to 2.0% by weight (abstract). The ophthalmologically active agent may be an antiallergic agent containing basic groups, including basic heterocycles, such as pyridine and piperidine (col. 4, lines 2-9). The salt/buffer functions as a viscosity reducing agent; choices of salts include sodium chloride and potassium chloride (col. 3, lines 45-50 and claim 5). Sodium chloride is exemplified in an amount of 0.9% w/v (Example 2), and therefore the skilled artisan would be sufficiently motivated to prepare the aqueous solution with sodium chloride, with a reasonable expectation of forming the ophthalmic composition. The composition is prepared by dissolving active ingredient(s) and inorganic salt(s) in sterile water, followed by mixing with a dispersion of the polymer in sterile water, to form a homogeneous solution (col. 5, lines 1-11). The composition is administered as a liquid and obtains a desired beneficial effect of the active agent in the eye, while simultaneously reducing any discomfort in the patient's eye, as compared to the administration of a composition in gel form. The composition also provides for an



Application/Control Number: 10/500,354 Page 4

Art Unit: 1611

additional wetting effect while providing for a better contact and thus a controlled absorption of active agent into the eye (col. 2, lines 10-18).

While Lehmussaari teaches the steps of preparing an aqueous preparation comprising an ophthalmic agent and sodium chloride, and teaches the ophthalmically active agent may be an antiallergic agent containing basic groups, including basic heterocycles, such as pyridine and piperidine, Lehmussaari does not specifically teach that the antiallergic agent is bepotastine. Lehmussaari also does not specifically teach that the amount of sodium chloride is a light-stabilizing effective amount (claim 1), or that the antiallergic agent is light-stabilized (claim 13).

Kita teaches that the benzenesulfonic acid salt or benzoic acid salt of (S)-4-[4-[4-chlorophenyl](2-pyridyl)methoxy]piperidino]butanoic acid (i.e., bepotastine) is excellent in antihistaminic activity and antiallergic activity, has little hygroscopicity and excellent in physicochemical stability, so that it is particularly suitable compound as a medicine. Kita et al also teach that its present invention relates to a medical composition containing the compound as an effective ingredient (see col. 1, lines 10-22).

Araki teaches a stabilized liquid preparation having improved light stability, comprising an aqueous solution containing sitafloxacin and sodium chloride (abstract). The light stabilizing effect is enhanced with an increase of the sodium chloride concentration; a particularly high stabilizing effect is obtained at a sodium chloride concentration of 0.1% or higher (paragraph [0055]). The liquid preparation is suitable



DOCKET

Explore Litigation Insights



Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time** alerts and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.

